Sponsor: Cullinan Pearl
Sponsor Study ID: CLN-081-001
Study Title: A Phase 1/2a, Open Label, Multi Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN 081 in Patients With Non Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
CTO #: 103183
NCT Number: NCT04036682
Phase: I/II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lung
Study Objectives: CLN-081-101 is a Phase 1/2a, open label, multi-center study of CLN-081 in patients with NSCLC (non small cell lung cancer) harboring EGFR (epidermal growth factor receptor) exon 20 insertion mutations, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.